NO312956B1 - Hydroksyaminsyrederivater for anvendelse ved behandling av sykdommer relatert til bindevevsdegradering, samt farmasöytiskpreparat inneholdende disse - Google Patents
Hydroksyaminsyrederivater for anvendelse ved behandling av sykdommer relatert til bindevevsdegradering, samt farmasöytiskpreparat inneholdende disse Download PDFInfo
- Publication number
- NO312956B1 NO312956B1 NO19984112A NO984112A NO312956B1 NO 312956 B1 NO312956 B1 NO 312956B1 NO 19984112 A NO19984112 A NO 19984112A NO 984112 A NO984112 A NO 984112A NO 312956 B1 NO312956 B1 NO 312956B1
- Authority
- NO
- Norway
- Prior art keywords
- oxo
- hydroxy
- methylpropyl
- pyrrolidinediacetamide
- phenylethyl
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 239000002253 acid Substances 0.000 title abstract description 15
- 201000010099 disease Diseases 0.000 title abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 title abstract description 13
- 210000002808 connective tissue Anatomy 0.000 title abstract description 10
- 230000008354 tissue degradation Effects 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 209
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 13
- -1 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl Chemical group 0.000 claims description 107
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 98
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 72
- VJBMZFLBFXTGRG-UHFFFAOYSA-N 2-[1-(2-amino-2-oxoethyl)pyrrolidin-3-yl]acetamide Chemical compound NC(=O)CC1CCN(CC(N)=O)C1 VJBMZFLBFXTGRG-UHFFFAOYSA-N 0.000 claims description 67
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- AKOXEDTYBMYZBX-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonylamino]-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetamide Chemical compound O=C1C(CC(C)C)(C(NS(=O)(=O)C=2C=CC(F)=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 AKOXEDTYBMYZBX-UHFFFAOYSA-N 0.000 claims description 5
- VNNFMFBXONUMCF-UHFFFAOYSA-N n-hydroxy-3-[(4-methoxyphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]propanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC(C(=O)NO)C1(CC(C)C)C(=O)N(CCC=2C=CC=CC=2)CC1 VNNFMFBXONUMCF-UHFFFAOYSA-N 0.000 claims description 5
- ZHBITEICRHRMSF-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-[1-[2-(4-fluorophenyl)ethyl]-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]-n-hydroxybutanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=C(F)C=C1 ZHBITEICRHRMSF-UHFFFAOYSA-N 0.000 claims description 4
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- SPJBQTOOMATWGZ-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetamide Chemical compound O=C1C(CC(C)C)(CC(=O)NO)CCN1CCC1=CC=CC=C1 SPJBQTOOMATWGZ-UHFFFAOYSA-N 0.000 claims description 4
- IQPABXIEJYTXDE-UHFFFAOYSA-N n-hydroxy-2-[4-(2-methylpropyl)-5-oxo-1-(2-phenylethyl)pyrazolidin-4-yl]acetamide;hydrochloride Chemical compound Cl.O=C1C(CC(C)C)(CC(=O)NO)CNN1CCC1=CC=CC=C1 IQPABXIEJYTXDE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- YWACDWPOKNFSCJ-UHFFFAOYSA-N 2-[1-benzyl-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]-n-hydroxyacetamide Chemical compound O=C1C(CC(C)C)(CC(=O)NO)CCN1CC1=CC=CC=C1 YWACDWPOKNFSCJ-UHFFFAOYSA-N 0.000 claims description 3
- PUYZYUNIQCECCA-UHFFFAOYSA-N 4-(5,6-difluoro-1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(F)=C(F)C=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 PUYZYUNIQCECCA-UHFFFAOYSA-N 0.000 claims description 3
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- SPJBQTOOMATWGZ-GOSISDBHSA-N n-hydroxy-2-[(3s)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetamide Chemical compound O=C1[C@](CC(C)C)(CC(=O)NO)CCN1CCC1=CC=CC=C1 SPJBQTOOMATWGZ-GOSISDBHSA-N 0.000 claims description 3
- WHHPRZWMCKUCKG-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetamide Chemical compound O=C1C(CC(C)C)(CC(=O)NO)CC(=O)N1CCC1=CC=CC=C1 WHHPRZWMCKUCKG-UHFFFAOYSA-N 0.000 claims description 3
- NDEFRBKEXJIVSP-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-(3-oxo-1h-isoindol-2-yl)butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 NDEFRBKEXJIVSP-UHFFFAOYSA-N 0.000 claims description 3
- LTTKDPWVEREJPO-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]propanamide Chemical compound O=C1C(CC(C)C)(C(C)C(=O)NO)CCN1CCC1=CC=CC=C1 LTTKDPWVEREJPO-UHFFFAOYSA-N 0.000 claims description 3
- TURFNQXUHHQVHU-UHFFFAOYSA-N n-hydroxy-2-[4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]acetamide Chemical compound O=C1C(CC(C)C)(CC(=O)NO)NC(=O)N1CCC1=CC=CC=C1 TURFNQXUHHQVHU-UHFFFAOYSA-N 0.000 claims description 3
- VKOLIMGKCAZEQO-UHFFFAOYSA-N n-hydroxy-4-[(4-methoxyphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCC(C(=O)NO)C1(CC(C)C)C(=O)N(CCC=2C=CC=CC=2)CC1 VKOLIMGKCAZEQO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- OZEAJWYJXIQKCS-UHFFFAOYSA-N 2-[1-(2-amino-2-oxoethyl)-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]acetamide Chemical compound CC(C)CC1(CC(N)=O)CCN(CC(N)=O)C1=O OZEAJWYJXIQKCS-UHFFFAOYSA-N 0.000 claims description 2
- VOIDVCNCHPCBQB-GBAZGAGXSA-N 4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[(3s)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound C([C@@](C1=O)(CC(C)C)C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CN1CCC1=CC=CC=C1 VOIDVCNCHPCBQB-GBAZGAGXSA-N 0.000 claims description 2
- RWCJVIUBYPVBRT-UHFFFAOYSA-N 4-(5,6-difluoro-3-oxo-1h-isoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(F)=C(F)C=C3C2)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 RWCJVIUBYPVBRT-UHFFFAOYSA-N 0.000 claims description 2
- CZXZLIFQSJOEHY-UHFFFAOYSA-N 4-(5-amino-1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(N)=CC=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 CZXZLIFQSJOEHY-UHFFFAOYSA-N 0.000 claims description 2
- QYWDKCVTYMLZJI-UHFFFAOYSA-N 4-(5-fluoro-1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(F)=CC=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 QYWDKCVTYMLZJI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- UHHNNSMDLFTQPK-UHFFFAOYSA-N n-hydroxy-2-[3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]acetamide Chemical compound O=C1C(CC(C)C)(CC(=O)NO)N(C)C(=O)N1CCC1=CC=CC=C1 UHHNNSMDLFTQPK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 235000012976 tarts Nutrition 0.000 claims 3
- PXQWQPUJBFVCCP-UHFFFAOYSA-N 4-(1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=C(CCCC3)C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 PXQWQPUJBFVCCP-UHFFFAOYSA-N 0.000 claims 2
- AGSDZMBKNYVQQN-UHFFFAOYSA-N n-[4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxobutyl]-3-nitrobenzamide Chemical compound O=C1C(CC(C)C)(C(CCNC(=O)C=2C=C(C=CC=2)[N+]([O-])=O)C(=O)NO)CCN1CCC1=CC=CC=C1 AGSDZMBKNYVQQN-UHFFFAOYSA-N 0.000 claims 2
- FIJFAMLBDRBDEG-UHFFFAOYSA-N n-hydroxy-4-[(4-methylphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCNS(=O)(=O)C=2C=CC(C)=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 FIJFAMLBDRBDEG-UHFFFAOYSA-N 0.000 claims 2
- NSKOJHJTWCJKKB-UHFFFAOYSA-N 2-[1-(2-amino-2-oxoethyl)-2-benzylpyrrolidin-3-yl]acetamide Chemical compound C1(=CC=CC=C1)CC1N(CCC1CC(=O)N)CC(=O)N NSKOJHJTWCJKKB-UHFFFAOYSA-N 0.000 claims 1
- YOGNVGLCELKBLW-UHFFFAOYSA-N 3,4-difluoro-n-[4-(hydroxyamino)-3-[3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxobutyl]benzamide Chemical compound O=C1C(CCO)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 YOGNVGLCELKBLW-UHFFFAOYSA-N 0.000 claims 1
- ALSPOKBRVRTPFV-UHFFFAOYSA-N 3,4-difluoro-n-[4-(hydroxyamino)-3-[3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxobutyl]benzamide Chemical compound O=C1C(CCCO)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 ALSPOKBRVRTPFV-UHFFFAOYSA-N 0.000 claims 1
- QUQGAAUCCQWUSJ-UHFFFAOYSA-N 3-fluoro-n-[4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxobutyl]benzamide Chemical compound O=C1C(CC(C)C)(C(CCNC(=O)C=2C=C(F)C=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 QUQGAAUCCQWUSJ-UHFFFAOYSA-N 0.000 claims 1
- IKASRIJOYIPIPS-UHFFFAOYSA-N 4-(1,3-dioxo-5-propoxyisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C2=CC(OCCC)=CC=C2C(=O)N1CCC(C(=O)NO)C(C1=O)(CC(C)C)CCN1CCC1=CC=CC=C1 IKASRIJOYIPIPS-UHFFFAOYSA-N 0.000 claims 1
- MZOICIUWWUALFK-UHFFFAOYSA-N 4-[1,3-dioxo-5-(trifluoromethyl)isoindol-2-yl]-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(=CC=C3C2=O)C(F)(F)F)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 MZOICIUWWUALFK-UHFFFAOYSA-N 0.000 claims 1
- JEUVHKYCBSQEAK-UHFFFAOYSA-N 4-fluoro-n-[4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxobutyl]benzamide Chemical compound O=C1C(CC(C)C)(C(CCNC(=O)C=2C=CC(F)=CC=2)C(=O)NO)CCN1CCC1=CC=CC=C1 JEUVHKYCBSQEAK-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract description 8
- 208000025865 Ulcer Diseases 0.000 abstract description 8
- 230000036269 ulceration Effects 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 108010026132 Gelatinases Proteins 0.000 abstract description 7
- 102000013382 Gelatinases Human genes 0.000 abstract description 7
- 229940088598 enzyme Drugs 0.000 abstract description 7
- 108060005980 Collagenase Proteins 0.000 abstract description 6
- 102000029816 Collagenase Human genes 0.000 abstract description 6
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 229960002424 collagenase Drugs 0.000 abstract description 6
- 108091007196 stromelysin Proteins 0.000 abstract description 6
- 239000011159 matrix material Substances 0.000 abstract description 5
- 206010053555 Arthritis bacterial Diseases 0.000 abstract description 4
- 208000004575 Infectious Arthritis Diseases 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract description 4
- 230000002500 effect on skin Effects 0.000 abstract description 4
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 208000007565 gingivitis Diseases 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 4
- 201000001245 periodontitis Diseases 0.000 abstract description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 4
- 201000001223 septic arthritis Diseases 0.000 abstract description 4
- 208000029725 Metabolic bone disease Diseases 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 289
- 239000000243 solution Substances 0.000 description 271
- 238000002360 preparation method Methods 0.000 description 219
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 202
- 238000005481 NMR spectroscopy Methods 0.000 description 186
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 162
- 235000019439 ethyl acetate Nutrition 0.000 description 144
- 239000000460 chlorine Substances 0.000 description 134
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 133
- 239000000203 mixture Substances 0.000 description 133
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 125
- 239000003921 oil Substances 0.000 description 99
- 235000019198 oils Nutrition 0.000 description 99
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 75
- 239000002480 mineral oil Substances 0.000 description 75
- 235000010446 mineral oil Nutrition 0.000 description 75
- 239000007787 solid Substances 0.000 description 66
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 62
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 58
- 238000000034 method Methods 0.000 description 58
- 239000007788 liquid Substances 0.000 description 49
- 238000010626 work up procedure Methods 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 238000000746 purification Methods 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 28
- 239000010410 layer Substances 0.000 description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 27
- 239000001301 oxygen Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 26
- 238000010898 silica gel chromatography Methods 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000012267 brine Substances 0.000 description 23
- 238000002844 melting Methods 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- 230000008018 melting Effects 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 238000005804 alkylation reaction Methods 0.000 description 16
- 239000006260 foam Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 239000011734 sodium Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000029936 alkylation Effects 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 229940058172 ethylbenzene Drugs 0.000 description 10
- 150000003951 lactams Chemical class 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 9
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- OQYDTCYMYOOVPD-UHFFFAOYSA-N tert-butyl 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetate Chemical compound O=C1C(CC(C)C)(CC(=O)OC(C)(C)C)CCN1CCC1=CC=CC=C1 OQYDTCYMYOOVPD-UHFFFAOYSA-N 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 7
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical compound CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- FGEKTVAHFDQHBU-UHFFFAOYSA-N dioxoruthenium;hydrate Chemical compound O.O=[Ru]=O FGEKTVAHFDQHBU-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- BVRKOQJETMBIDK-VIFPVBQESA-N (2s)-2-amino-n-methyl-3-phenylpropanamide Chemical compound CNC(=O)[C@@H](N)CC1=CC=CC=C1 BVRKOQJETMBIDK-VIFPVBQESA-N 0.000 description 3
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- SFFQHXPWDLQXLA-UHFFFAOYSA-N ethyl 2-[3-(2-methylpropyl)-2-oxo-3-prop-1-en-2-ylpyrrolidin-1-yl]acetate Chemical compound CCOC(=O)CN1CCC(CC(C)C)(C(C)=C)C1=O SFFQHXPWDLQXLA-UHFFFAOYSA-N 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
- 229940091173 hydantoin Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- NDGRWYRVNANFNB-UHFFFAOYSA-N pyrazolidin-3-one Chemical class O=C1CCNN1 NDGRWYRVNANFNB-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 3
- KGKWCQHKNGKJPG-UHFFFAOYSA-N tert-butyl 3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-(2-methylpropyl)-2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)CC1(CC(C)C)CCN(C(=O)OC(C)(C)C)C1=O KGKWCQHKNGKJPG-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- GKZJJXFFNOSPHJ-UHFFFAOYSA-N 1-(2-phenylethyl)pyrrolidin-2-one Chemical compound O=C1CCCN1CCC1=CC=CC=C1 GKZJJXFFNOSPHJ-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HJGUTUBKMMJWQD-UHFFFAOYSA-N 2-[1-benzyl-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]-4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(O)=O)CCN1CC1=CC=CC=C1 HJGUTUBKMMJWQD-UHFFFAOYSA-N 0.000 description 2
- WZVZXEOOFLWECB-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetic acid Chemical compound O=C1C(CC(C)C)(CC(O)=O)CC(=O)N1CCC1=CC=CC=C1 WZVZXEOOFLWECB-UHFFFAOYSA-N 0.000 description 2
- UXAPMZWBQGGUTF-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-n-phenylmethoxypropanamide Chemical compound O=C1C(CC(C)C)(C(C)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 UXAPMZWBQGGUTF-UHFFFAOYSA-N 0.000 description 2
- OKENDFWSHRABBP-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetic acid Chemical compound O=C1C(CC(C)C)(CC(O)=O)CCN1CCC1=CC=CC=C1 OKENDFWSHRABBP-UHFFFAOYSA-N 0.000 description 2
- QBZDYWSBIYUBKR-UHFFFAOYSA-N 2-[3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]acetic acid Chemical compound O=C1C(CC(C)C)(CC(O)=O)N(C)C(=O)N1CCC1=CC=CC=C1 QBZDYWSBIYUBKR-UHFFFAOYSA-N 0.000 description 2
- YQDMIEXGMBQXBS-UHFFFAOYSA-N 2-[4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]-n-phenylmethoxyacetamide Chemical compound N1C(=O)N(CCC=2C=CC=CC=2)C(=O)C1(CC(C)C)CC(=O)NOCC1=CC=CC=C1 YQDMIEXGMBQXBS-UHFFFAOYSA-N 0.000 description 2
- YOEPSFWNAFEVMV-UHFFFAOYSA-N 2-[4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]acetic acid Chemical compound O=C1C(CC(C)C)(CC(O)=O)NC(=O)N1CCC1=CC=CC=C1 YOEPSFWNAFEVMV-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 2
- XVPPUMORXZYACJ-UHFFFAOYSA-N 3-(2-methylpropyl)-1-(2-phenylethyl)pyrrolidin-2-one Chemical compound O=C1C(CC(C)C)CCN1CCC1=CC=CC=C1 XVPPUMORXZYACJ-UHFFFAOYSA-N 0.000 description 2
- OYYMYMUDJBKIPW-UHFFFAOYSA-N 3-(2-methylpropyl)-1-trimethylsilylpyrrolidin-2-one Chemical compound CC(C)CC1CCN([Si](C)(C)C)C1=O OYYMYMUDJBKIPW-UHFFFAOYSA-N 0.000 description 2
- HPPWRXDEIJLABV-UHFFFAOYSA-N 3-(2-methylpropyl)-3-prop-1-en-2-ylpyrrolidin-2-one Chemical compound CC(C)CC1(C(C)=C)CCNC1=O HPPWRXDEIJLABV-UHFFFAOYSA-N 0.000 description 2
- JVTVLVBVGWDCOG-UHFFFAOYSA-N 3-(2-methylpropyl)pyrrolidin-2-one Chemical compound CC(C)CC1CCNC1=O JVTVLVBVGWDCOG-UHFFFAOYSA-N 0.000 description 2
- MIXHGZZZNMOAFG-UHFFFAOYSA-N 3-methyl-1-(2-phenylethyl)imidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)CN1CCC1=CC=CC=C1 MIXHGZZZNMOAFG-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- FLKJPGYTYYLKIU-UHFFFAOYSA-N benzyl 3-oxo-2-(2-phenylethyl)pyrazolidine-1-carboxylate Chemical compound C1CC(=O)N(CCC=2C=CC=CC=2)N1C(=O)OCC1=CC=CC=C1 FLKJPGYTYYLKIU-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000002442 collagenase inhibitor Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HQHGPUCIYLXTLC-UHFFFAOYSA-N ethyl 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetate Chemical compound O=C1C(CC(=O)OCC)(CC(C)C)CCN1CCC1=CC=CC=C1 HQHGPUCIYLXTLC-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000001469 hydantoins Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- COCSLFFWEWBZSM-UHFFFAOYSA-N n-methyl-2-[3-(2-methylpropyl)-2-oxo-3-prop-1-en-2-ylpyrrolidin-1-yl]acetamide Chemical compound CNC(=O)CN1CCC(CC(C)C)(C(C)=C)C1=O COCSLFFWEWBZSM-UHFFFAOYSA-N 0.000 description 2
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MJVZCGGFLBAIDR-UHFFFAOYSA-N tert-butyl 3-methyl-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]but-3-enoate Chemical compound O=C1C(CC(C)C)(C(C(C)=C)C(=O)OC(C)(C)C)CCN1CCC1=CC=CC=C1 MJVZCGGFLBAIDR-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- LIBDTAYIDBPBRN-LURJTMIESA-N (2s)-2-amino-n,4-dimethylpentanamide Chemical compound CNC(=O)[C@@H](N)CC(C)C LIBDTAYIDBPBRN-LURJTMIESA-N 0.000 description 1
- RRONHWAVOYADJL-HNNXBMFYSA-N (2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-HNNXBMFYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- AEMWUHCKKDPRSK-UHFFFAOYSA-N (ne)-n-diazo-2,4,6-tri(propan-2-yl)benzenesulfonamide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)N=[N+]=[N-])C(C(C)C)=C1 AEMWUHCKKDPRSK-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UUSLLECLCKTJQF-UHFFFAOYSA-N 2-(bromomethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CBr)C(=O)C2=C1 UUSLLECLCKTJQF-UHFFFAOYSA-N 0.000 description 1
- DUCBSHDQTBWWLC-UHFFFAOYSA-N 2-[(2-chlorophenyl)methyl-(1,1,2,2,3,3,4,4,4-nonafluorobutylsulfonyl)amino]-n-hydroxypropanamide Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(C(C)C(=O)NO)CC1=CC=CC=C1Cl DUCBSHDQTBWWLC-UHFFFAOYSA-N 0.000 description 1
- SNEIBBSUBBDEAT-UHFFFAOYSA-N 2-[1-(2-amino-2-oxoethyl)-2-oxo-3-propan-2-ylpyrrolidin-3-yl]acetamide Chemical compound CC(C)C1(C(N(CC1)CC(=O)N)=O)CC(=O)N SNEIBBSUBBDEAT-UHFFFAOYSA-N 0.000 description 1
- DLGMNTIFORCVBQ-UHFFFAOYSA-N 2-[1-benzyl-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]-4-(1,3-dioxoisoindol-2-yl)-n-hydroxybutanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CCN1CC1=CC=CC=C1 DLGMNTIFORCVBQ-UHFFFAOYSA-N 0.000 description 1
- JAVSLADGJLXNFM-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)pyrrolidin-3-yl]-n-phenylmethoxyacetamide Chemical compound C1C(=O)N(CCC=2C=CC=CC=2)C(=O)C1(CC(C)C)CC(=O)NOCC1=CC=CC=C1 JAVSLADGJLXNFM-UHFFFAOYSA-N 0.000 description 1
- LHTSDUXWDMMPOT-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-thiophen-2-ylsulfanylbutanoic acid Chemical compound O=C1C(CC(C)C)(C(CCSC=2SC=CC=2)C(O)=O)CCN1CCC1=CC=CC=C1 LHTSDUXWDMMPOT-UHFFFAOYSA-N 0.000 description 1
- LTZDDZSJDOVOLJ-UHFFFAOYSA-N 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]propanoic acid Chemical compound O=C1C(CC(C)C)(C(C)C(O)=O)CCN1CCC1=CC=CC=C1 LTZDDZSJDOVOLJ-UHFFFAOYSA-N 0.000 description 1
- KKSQPZZVSNVLCV-UHFFFAOYSA-N 2-[3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)imidazolidin-4-yl]-n-phenylmethoxyacetamide Chemical compound CN1C(=O)N(CCC=2C=CC=CC=2)C(=O)C1(CC(C)C)CC(=O)NOCC1=CC=CC=C1 KKSQPZZVSNVLCV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BBSFEDLKGRMARS-UHFFFAOYSA-N 2-amino-4-methyl-2-prop-1-en-2-ylpentanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC(C)CC(N)(C(C)=C)C(O)=O BBSFEDLKGRMARS-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- HACRKYQRZABURO-UHFFFAOYSA-N 2-phenylethyl isocyanate Chemical compound O=C=NCCC1=CC=CC=C1 HACRKYQRZABURO-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- IPXNXMNCBXHYLQ-UHFFFAOYSA-N 2-pyrrolidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCC1 IPXNXMNCBXHYLQ-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LEPVFRWDYAERFI-UHFFFAOYSA-N 3,4-difluoro-n-[3-[3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxo-4-(phenylmethoxyamino)butyl]benzamide Chemical compound O=C1C(CCO)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 LEPVFRWDYAERFI-UHFFFAOYSA-N 0.000 description 1
- WAXXSHBUFQVFCZ-UHFFFAOYSA-N 3,4-difluoro-n-[3-[3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-oxo-4-(phenylmethoxyamino)butyl]benzamide Chemical compound O=C1C(CCCO)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 WAXXSHBUFQVFCZ-UHFFFAOYSA-N 0.000 description 1
- ZNDOMIJRKSYUQL-UHFFFAOYSA-N 3,4-difluoro-n-[4-oxo-3-[2-oxo-1-(2-phenylethyl)-3-prop-1-en-2-ylpyrrolidin-3-yl]-4-(phenylmethoxyamino)butyl]benzamide Chemical compound O=C1C(C(=C)C)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 ZNDOMIJRKSYUQL-UHFFFAOYSA-N 0.000 description 1
- KEORNCNWZNIONG-UHFFFAOYSA-N 3-[(4-methoxyphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-n-phenylmethoxypropanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC(C1(CC(C)C)C(N(CCC=2C=CC=CC=2)CC1)=O)C(=O)NOCC1=CC=CC=C1 KEORNCNWZNIONG-UHFFFAOYSA-N 0.000 description 1
- XBVQVHITHYFJSQ-UHFFFAOYSA-N 3-[(4-methoxyphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC(C(O)=O)C1(CC(C)C)C(=O)N(CCC=2C=CC=CC=2)CC1 XBVQVHITHYFJSQ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GXHIOZHDNIONPT-UHFFFAOYSA-N 4,5,6,7-tetrafluoroisoindole-1,3-dione Chemical compound FC1=C(F)C(F)=C2C(=O)NC(=O)C2=C1F GXHIOZHDNIONPT-UHFFFAOYSA-N 0.000 description 1
- SJTJZLUESDHJJB-UHFFFAOYSA-N 4,7-difluoroisoindole-1,3-dione Chemical compound FC1=CC=C(F)C2=C1C(=O)NC2=O SJTJZLUESDHJJB-UHFFFAOYSA-N 0.000 description 1
- SILOKVUMEGTAPZ-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-n-phenylmethoxybutanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 SILOKVUMEGTAPZ-UHFFFAOYSA-N 0.000 description 1
- SDUCGUQVIUUYMU-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanoic acid Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(O)=O)CCN1CCC1=CC=CC=C1 SDUCGUQVIUUYMU-UHFFFAOYSA-N 0.000 description 1
- VOIDVCNCHPCBQB-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 VOIDVCNCHPCBQB-UHFFFAOYSA-N 0.000 description 1
- VREUWWFCQOOHFB-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]pentanamide Chemical compound O=C1C(CC(C)C)(C(CC(C)N2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 VREUWWFCQOOHFB-UHFFFAOYSA-N 0.000 description 1
- MXXTYAPJKNGSIJ-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(3-phenylpropyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(=O)NO)CCN1CCCC1=CC=CC=C1 MXXTYAPJKNGSIJ-UHFFFAOYSA-N 0.000 description 1
- LOWNQFRETFCVKP-UHFFFAOYSA-N 4-(4,7-difluoro-1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=C(C(=CC=C3F)F)C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 LOWNQFRETFCVKP-UHFFFAOYSA-N 0.000 description 1
- CZJDJDHKLVUBOL-UHFFFAOYSA-N 4-(5,6-dichloro-1,3-dioxoisoindol-2-yl)-n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(Cl)=C(Cl)C=C3C2=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 CZJDJDHKLVUBOL-UHFFFAOYSA-N 0.000 description 1
- RMJUCXSSWTWGRT-UHFFFAOYSA-N 4-[(3,4-difluorobenzoyl)amino]-2-[2-oxo-1-(2-phenylethyl)-3-prop-1-en-2-ylpyrrolidin-3-yl]butanoic acid Chemical compound O=C1C(C(=C)C)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(O)=O)CCN1CCC1=CC=CC=C1 RMJUCXSSWTWGRT-UHFFFAOYSA-N 0.000 description 1
- BBQSNRRQSOQIAY-UHFFFAOYSA-N 4-[(3,4-difluorobenzoyl)amino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanoic acid Chemical compound O=C1C(CC(C)C)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(O)=O)CCN1CCC1=CC=CC=C1 BBQSNRRQSOQIAY-UHFFFAOYSA-N 0.000 description 1
- FDXCFUZWNWSDEF-UHFFFAOYSA-N 4-[(3,4-difluorobenzoyl)amino]-2-[3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanoic acid Chemical compound O=C1C(CCCO)(C(CCNC(=O)C=2C=C(F)C(F)=CC=2)C(O)=O)CCN1CCC1=CC=CC=C1 FDXCFUZWNWSDEF-UHFFFAOYSA-N 0.000 description 1
- CODYPEDXEGXNQR-UHFFFAOYSA-N 4-[(4-methylphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-n-phenylmethoxybutanamide Chemical compound O=C1C(CC(C)C)(C(CCNS(=O)(=O)C=2C=CC(C)=CC=2)C(=O)NOCC=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 CODYPEDXEGXNQR-UHFFFAOYSA-N 0.000 description 1
- XUZKMQCHMKZNJV-UHFFFAOYSA-N 4-[(4-methylphenyl)sulfonylamino]-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanoic acid Chemical compound O=C1C(CC(C)C)(C(CCNS(=O)(=O)C=2C=CC(C)=CC=2)C(O)=O)CCN1CCC1=CC=CC=C1 XUZKMQCHMKZNJV-UHFFFAOYSA-N 0.000 description 1
- ROFGDCOBISHGRK-UHFFFAOYSA-N 4-fluoroisoindole-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)NC2=O ROFGDCOBISHGRK-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- BONIIQYTWOPUQI-UHFFFAOYSA-N 4-nitroisoindole-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)NC2=O BONIIQYTWOPUQI-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QJPBDGMPYPSJSF-UHFFFAOYSA-N 5,6-dichloroisoindole-1,3-dione Chemical compound C1=C(Cl)C(Cl)=CC2=C1C(=O)NC2=O QJPBDGMPYPSJSF-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- DVDRUQOUGHIYCB-UHFFFAOYSA-N 5-fluoroisoindole-1,3-dione Chemical compound FC1=CC=C2C(=O)NC(=O)C2=C1 DVDRUQOUGHIYCB-UHFFFAOYSA-N 0.000 description 1
- ANYWGXDASKQYAD-UHFFFAOYSA-N 5-nitroisoindole-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C(=O)NC(=O)C2=C1 ANYWGXDASKQYAD-UHFFFAOYSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- ZSBDPRIWBYHIAF-UHFFFAOYSA-N N-acetyl-acetamide Natural products CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- XWURZHGKODQZMK-UHFFFAOYSA-N O.[Ru]=O Chemical compound O.[Ru]=O XWURZHGKODQZMK-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- SWEDAZLCYJDAGW-UHFFFAOYSA-N Thiophene-2-thiol Chemical compound SC1=CC=CS1 SWEDAZLCYJDAGW-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ODBPKBWAGSAZBE-UHFFFAOYSA-N benzo[f]isoindole-1,3-dione Chemical compound C1=CC=C2C=C3C(=O)NC(=O)C3=CC2=C1 ODBPKBWAGSAZBE-UHFFFAOYSA-N 0.000 description 1
- AGTCMTUCMQLUMT-UHFFFAOYSA-N benzyl 3-oxopyrazolidine-1-carboxylate Chemical compound C1CC(=O)NN1C(=O)OCC1=CC=CC=C1 AGTCMTUCMQLUMT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- DNXFCUINRMVXSF-UHFFFAOYSA-N chloroboron;methylsulfanylmethane Chemical compound Cl[B].CSC DNXFCUINRMVXSF-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- GRKHUQUPFHCOOD-UHFFFAOYSA-N ethyl 2-[3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)pyrrolidin-3-yl]acetate Chemical compound O=C1C(CC(=O)OCC)(CC(C)C)CC(=O)N1CCC1=CC=CC=C1 GRKHUQUPFHCOOD-UHFFFAOYSA-N 0.000 description 1
- WZIWYLYTRDBSNT-UHFFFAOYSA-N ethyl 2-[3-(2-methylpropyl)-2-oxo-3-prop-1-en-2-ylpyrrolidin-1-yl]-3-phenylpropanoate Chemical compound C1CC(CC(C)C)(C(C)=C)C(=O)N1C(C(=O)OCC)CC1=CC=CC=C1 WZIWYLYTRDBSNT-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OCLKNWYPBUBHQS-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-(4-nitro-1,3-dioxoisoindol-2-yl)butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=C(C=CC=C3C2=O)[N+]([O-])=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 OCLKNWYPBUBHQS-UHFFFAOYSA-N 0.000 description 1
- OMPUVJZEGFCJQZ-UHFFFAOYSA-N n-hydroxy-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-(5-nitro-1,3-dioxoisoindol-2-yl)butanamide Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(=CC=C3C2=O)[N+]([O-])=O)=O)C(=O)NO)CCN1CCC1=CC=CC=C1 OMPUVJZEGFCJQZ-UHFFFAOYSA-N 0.000 description 1
- MYGGKVUYZDVWQV-UHFFFAOYSA-N n-methyl-2-[3-(2-methylpropyl)-2-oxo-3-prop-1-en-2-ylpyrrolidin-1-yl]-3-phenylpropanamide Chemical compound C1CC(CC(C)C)(C(C)=C)C(=O)N1C(C(=O)NC)CC1=CC=CC=C1 MYGGKVUYZDVWQV-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 208000011932 ovarian sarcoma Diseases 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KGKWCQHKNGKJPG-LJQANCHMSA-N tert-butyl (3s)-3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-(2-methylpropyl)-2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)C[C@]1(CC(C)C)CCN(C(=O)OC(C)(C)C)C1=O KGKWCQHKNGKJPG-LJQANCHMSA-N 0.000 description 1
- MIIQJLROSSHCAU-CQSZACIVSA-N tert-butyl 2-[(3s)-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@]1(CC(C)C)CCNC1=O MIIQJLROSSHCAU-CQSZACIVSA-N 0.000 description 1
- PRSLXQBOTZEWMW-UHFFFAOYSA-N tert-butyl 2-[1-benzyl-3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]-3-methylbut-3-enoate Chemical compound O=C1C(CC(C)C)(C(C(C)=C)C(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 PRSLXQBOTZEWMW-UHFFFAOYSA-N 0.000 description 1
- MGKPBYAIZRQWMV-UHFFFAOYSA-N tert-butyl 2-[2-oxo-1-(2-phenylethyl)-3-prop-1-en-2-ylpyrrolidin-3-yl]acetate Chemical compound O=C1C(C(=C)C)(CC(=O)OC(C)(C)C)CCN1CCC1=CC=CC=C1 MGKPBYAIZRQWMV-UHFFFAOYSA-N 0.000 description 1
- RPCJJZOPZAWELW-UHFFFAOYSA-N tert-butyl 2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]-4-thiophen-2-ylsulfanylbutanoate Chemical compound O=C1C(CC(C)C)(C(CCSC=2SC=CC=2)C(=O)OC(C)(C)C)CCN1CCC1=CC=CC=C1 RPCJJZOPZAWELW-UHFFFAOYSA-N 0.000 description 1
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 1
- QIKGXCGYRAMYNJ-UHFFFAOYSA-N tert-butyl 3-methyl-2-[3-(2-methylpropyl)-2-oxopyrrolidin-3-yl]but-3-enoate Chemical compound CC(C)(C)OC(=O)C(C(C)=C)C1(CC(C)C)CCNC1=O QIKGXCGYRAMYNJ-UHFFFAOYSA-N 0.000 description 1
- GHUNUSAWVVKGNZ-UHFFFAOYSA-N tert-butyl 4-(5,6-difluoro-3-oxo-1h-isoindol-2-yl)-2-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)pyrrolidin-3-yl]butanoate Chemical compound O=C1C(CC(C)C)(C(CCN2C(C3=CC(F)=C(F)C=C3C2)=O)C(=O)OC(C)(C)C)CCN1CCC1=CC=CC=C1 GHUNUSAWVVKGNZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 150000003953 γ-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1309896P | 1996-03-08 | 1996-03-08 | |
| PCT/US1997/002568 WO1997032846A1 (en) | 1996-03-08 | 1997-03-03 | Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984112D0 NO984112D0 (no) | 1998-09-07 |
| NO984112L NO984112L (no) | 1998-11-06 |
| NO312956B1 true NO312956B1 (no) | 2002-07-22 |
Family
ID=21758301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984112A NO312956B1 (no) | 1996-03-08 | 1998-09-07 | Hydroksyaminsyrederivater for anvendelse ved behandling av sykdommer relatert til bindevevsdegradering, samt farmasöytiskpreparat inneholdende disse |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5712300A (enExample) |
| EP (1) | EP0898562B1 (enExample) |
| JP (1) | JP2000506163A (enExample) |
| KR (1) | KR19990087597A (enExample) |
| CN (1) | CN1210517A (enExample) |
| AT (1) | ATE231490T1 (enExample) |
| AU (1) | AU707180B2 (enExample) |
| BR (1) | BR9707947A (enExample) |
| DE (1) | DE69718634T2 (enExample) |
| DK (1) | DK0898562T3 (enExample) |
| ES (1) | ES2191823T3 (enExample) |
| ID (1) | ID16144A (enExample) |
| MY (1) | MY117762A (enExample) |
| NO (1) | NO312956B1 (enExample) |
| NZ (1) | NZ330922A (enExample) |
| PE (1) | PE55698A1 (enExample) |
| PL (1) | PL328693A1 (enExample) |
| PT (1) | PT898562E (enExample) |
| RU (1) | RU2168497C2 (enExample) |
| TW (1) | TW448172B (enExample) |
| UA (1) | UA61906C2 (enExample) |
| WO (1) | WO1997032846A1 (enExample) |
| ZA (1) | ZA971902B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932579A (en) * | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
| WO1997048688A1 (en) * | 1996-06-21 | 1997-12-24 | Pharmacia & Upjohn Company | Thiadiazole amide mmp inhibitors |
| ATE289590T1 (de) * | 1996-09-27 | 2005-03-15 | Upjohn Co | Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren |
| GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| US6566373B2 (en) | 1997-05-06 | 2003-05-20 | Smithkline Beecham Corporation | Protease inhibitors |
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| US5883131A (en) * | 1997-07-09 | 1999-03-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| WO1999006340A2 (en) | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE69915004T2 (de) * | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| SK12452001A3 (sk) | 1999-03-03 | 2002-04-04 | The Procter & Gamble Company | Zlúčenina vytvárajúca inhibítor metaloproteinázy, farmaceutický prostriedok, spôsob prípravy liečiva a liečivo |
| WO2000051993A2 (en) | 1999-03-03 | 2000-09-08 | The Procter & Gamble Company | Dihetero-substituted metalloprotease inhibitors |
| EP1165546A2 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| AU2002230385A1 (en) * | 2000-09-25 | 2002-04-15 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| EP1355901A2 (en) | 2001-01-11 | 2003-10-29 | Bristol-Myers Squibb Pharma Company | 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) |
| CA2434044A1 (en) | 2001-01-11 | 2002-07-18 | Bristol-Myers Squibb Pharma Company | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| DE60207384T2 (de) * | 2001-03-01 | 2006-08-03 | Smithkline Beecham Corp. | Peptid-deformylase-hemmer |
| JP4314340B2 (ja) * | 2001-06-15 | 2009-08-12 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | ピロリジン二環性化合物 |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| TWI294778B (en) * | 2002-03-13 | 2008-03-21 | Smithkline Beecham Corp | Peptide deformylase inhibitors |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| PL374117A1 (en) * | 2002-05-29 | 2005-10-03 | Merck & Co, Inc. | Compounds useful in the treatment of anthrax and inhibiting lethal factor |
| US20050176686A1 (en) * | 2002-07-23 | 2005-08-11 | 4Sc Ag | Novel compounds as histone deacetylase inhibitors |
| EP1626961B1 (en) * | 2003-05-17 | 2011-11-02 | Korea Research Institute of Bioscience and Biotechnology | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| US7122560B2 (en) | 2003-06-18 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| EP1663201A4 (en) * | 2003-07-15 | 2009-10-28 | Korea Res Inst Of Bioscience | USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| KR101070036B1 (ko) * | 2003-07-23 | 2011-10-04 | 노르딕 바이오사이언스 에이/에스 | 골관절염에 대한 칼시토닌의 용도 |
| CN1950354A (zh) * | 2004-05-11 | 2007-04-18 | 默克公司 | N－磺酰化－氨基酸衍生物的制备方法 |
| US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| JP2008528624A (ja) * | 2005-01-28 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | フェニル置換ピロリドン |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US9738604B2 (en) | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
| US20140081017A1 (en) * | 2012-09-14 | 2014-03-20 | Methylgene Inc. | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents |
| WO2015024011A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| AU2014306451B2 (en) | 2013-08-16 | 2019-01-17 | Duke University | Substituted hydroxamic acid compounds |
| US9908851B2 (en) | 2013-08-16 | 2018-03-06 | Duke University | 2-piperidinyl substituted N,3-dihydroxybutanamides |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1360583A (en) * | 1918-02-18 | 1920-11-30 | Great Lakes Dredge And Dock Co | Car-dumper |
| EP0042100A1 (de) * | 1980-06-13 | 1981-12-23 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel |
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
| US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| ATE195117T1 (de) * | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| EP0712390B1 (en) * | 1993-08-02 | 1998-12-09 | Celltech Therapeutics Limited | Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors |
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
-
1997
- 1997-02-21 TW TW086102076A patent/TW448172B/zh not_active IP Right Cessation
- 1997-03-03 EP EP97908674A patent/EP0898562B1/en not_active Expired - Lifetime
- 1997-03-03 NZ NZ330922A patent/NZ330922A/xx unknown
- 1997-03-03 DK DK97908674T patent/DK0898562T3/da active
- 1997-03-03 ES ES97908674T patent/ES2191823T3/es not_active Expired - Lifetime
- 1997-03-03 BR BR9707947A patent/BR9707947A/pt active Search and Examination
- 1997-03-03 AT AT97908674T patent/ATE231490T1/de not_active IP Right Cessation
- 1997-03-03 UA UA98105283A patent/UA61906C2/uk unknown
- 1997-03-03 DE DE69718634T patent/DE69718634T2/de not_active Expired - Fee Related
- 1997-03-03 PT PT97908674T patent/PT898562E/pt unknown
- 1997-03-03 CN CN97192171A patent/CN1210517A/zh active Pending
- 1997-03-03 RU RU98118372/04A patent/RU2168497C2/ru not_active IP Right Cessation
- 1997-03-03 AU AU20525/97A patent/AU707180B2/en not_active Ceased
- 1997-03-03 JP JP9531784A patent/JP2000506163A/ja not_active Withdrawn
- 1997-03-03 PL PL97328693A patent/PL328693A1/xx unknown
- 1997-03-03 KR KR1019980707039A patent/KR19990087597A/ko not_active Abandoned
- 1997-03-03 WO PCT/US1997/002568 patent/WO1997032846A1/en not_active Ceased
- 1997-03-04 PE PE1997000155A patent/PE55698A1/es not_active Application Discontinuation
- 1997-03-04 US US08/811,821 patent/US5712300A/en not_active Expired - Fee Related
- 1997-03-05 ZA ZA971902A patent/ZA971902B/xx unknown
- 1997-03-06 ID IDP970713A patent/ID16144A/id unknown
- 1997-03-07 MY MYPI97000965A patent/MY117762A/en unknown
-
1998
- 1998-09-07 NO NO19984112A patent/NO312956B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO984112L (no) | 1998-11-06 |
| KR19990087597A (ko) | 1999-12-27 |
| TW448172B (en) | 2001-08-01 |
| PE55698A1 (es) | 1998-09-16 |
| DK0898562T3 (da) | 2003-05-12 |
| MY117762A (en) | 2004-08-30 |
| BR9707947A (pt) | 1999-07-27 |
| WO1997032846A1 (en) | 1997-09-12 |
| DE69718634D1 (de) | 2003-02-27 |
| ES2191823T3 (es) | 2003-09-16 |
| ZA971902B (en) | 1998-09-07 |
| UA61906C2 (en) | 2003-12-15 |
| JP2000506163A (ja) | 2000-05-23 |
| ATE231490T1 (de) | 2003-02-15 |
| CN1210517A (zh) | 1999-03-10 |
| ID16144A (id) | 1997-09-04 |
| DE69718634T2 (de) | 2003-10-30 |
| NO984112D0 (no) | 1998-09-07 |
| EP0898562A1 (en) | 1999-03-03 |
| AU2052597A (en) | 1997-09-22 |
| EP0898562B1 (en) | 2003-01-22 |
| RU2168497C2 (ru) | 2001-06-10 |
| PL328693A1 (en) | 1999-02-15 |
| AU707180B2 (en) | 1999-07-01 |
| US5712300A (en) | 1998-01-27 |
| PT898562E (pt) | 2003-06-30 |
| NZ330922A (en) | 2000-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312956B1 (no) | Hydroksyaminsyrederivater for anvendelse ved behandling av sykdommer relatert til bindevevsdegradering, samt farmasöytiskpreparat inneholdende disse | |
| TWI386405B (zh) | 咪唑衍生物 | |
| JPH11507368A (ja) | 置換（スルフィン酸、スルホン酸、またはスルホニルアミノもしくはスルフィニルアミノ）ｎ−［（アミノイミノメチル）フェニルアルキル］−アザ複素環アミド化合物 | |
| JP2006523710A (ja) | ホスホジエステラーゼ４インヒビター | |
| CZ296915B6 (cs) | Slouceniny inhibující proteázy retroviru | |
| JPH11505502A (ja) | マトリックスメタロプロテイナーゼ阻害剤としてのアリールスルホンアミド置換ヒドロキサム酸類 | |
| SK48499A3 (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors | |
| KR20050044407A (ko) | N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체 | |
| JPWO2006104280A1 (ja) | 糖尿病の予防・治療剤 | |
| EP2185537A1 (en) | Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions | |
| EP0821674A1 (en) | Cyclic amidino agents useful as nitric oxide synthase inhibitors | |
| AU2005238144B2 (en) | Imidazole derivatives used as TAFIa inhibitors | |
| US6201006B1 (en) | Aromatic amidine derivatives useful as selective thrombin inhibitors | |
| BG104216A (bg) | Производни на пиролидин-3-карбонови киселини и тяхното приложение като ендотелинови антагонисти | |
| NO841958L (no) | Nye indolforbindelser | |
| WO2002017912A1 (en) | Endothelin antagonists | |
| HU192243B (en) | Process for production of new indole derivates containing sulphur and physiologically acceptable acid-additional salts | |
| CA2019808A1 (en) | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | |
| US8710232B2 (en) | Imidazole derivatives used as TAFIa inhibitors | |
| CA2244903C (en) | Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation | |
| RU2826010C2 (ru) | Способ получения 3,5-дифтор-бензиламида (s)-3-гидрокси-1-(1h-индол-5-ил)-2-оксо-пирролидин-3-карбоновой кислоты | |
| CZ2000348A3 (cs) | Deriváty pyrrolidin-3-karboxylové kyseliny a jejich použití jako antagonistů endothelinu | |
| MXPA06011067A (en) | Imidazole derivatives used as tafia inhibitors |